Original Publication Date: 8 March, 2014
Publication / Source: Lung Cancer Management
Authors: Anna Manzo, Carminia Maria Della Corte, Lucia Festino, Morena Fasano, Fortunato Ciardiello & Floriana Morgillo
Lung cancers harboring mutations in the EGFR respond to EGF receptor-tyrosine kinase inhibitor, which at present represent the most appropriate treatment for EGFR mutation-positive advanced non-small-cell lung cancer. Unfortunately drug resistance invariably emerges with different known mechanisms, including the EGFR T790M mutation, MET gene amplification, EGFR amplification, mutations in the PIK3CA gene, mutations in the HER2 gene, IGF1R amplification, transformation of non-small-cell lung cancer into small-cell lung cancer and moreover epithelial-to-mesenchymal transition.